← All trials
NCT05370911
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2023
- Primary completion
- Feb 28, 2026
- Completion date
- Feb 28, 2027
- First posted
- May 12, 2022
- Last posted
- Nov 23, 2022
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yale UniversityLead sponsor
- Yale UniversityOverall official - principal investigator
- Yale UniversityReponsible party - principal investigator
- Yale UniversityStudy director
- Steven & Alexandra Cohen Children's Medical Center, New YorkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.